[{"address1": "180 North LaSalle Street", "address2": "Suite 1600", "city": "Chicago", "state": "IL", "zip": "60601", "country": "United States", "phone": "844 445 5704", "website": "https://www.xerispharma.com", "industry": "Biotechnology", "sector": "Healthcare", "longBusinessSummary": "Xeris Biopharma Holdings, Inc., a biopharmaceutical company, engages in developing and commercializing therapies in Illinois. The company offers Gvoke, a ready-to-use liquid-stable glucagon for the treatment of severe hypoglycemia pediatric and adult patients; Keveyis, a therapy for the treatment of hyperkalemic, hypokalemic, and related variants of primary periodic paralysis; and Recorlev, a cortisol synthesis inhibitor proved for the treatment of endogenous hypercortisolemia in adult patients with Cushing's syndrome. It is also developing XP-8121, a once-weekly subcutaneous injection of levothyroxine that is in phase I clinical trial for the treatment of hypothyroidism; and non-aqueous XeriSol and XeriJect technologies for various therapies. The company was incorporated in 2005 and is headquartered in Chicago, Illinois.", "fullTimeEmployees": 377, "companyOfficers": [{"maxAge": 1, "name": "Mr. Paul R. Edick", "age": 67, "title": "Chairman & CEO", "yearBorn": 1956, "fiscalYear": 2022, "totalPay": 1119599, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. John P. Shannon", "age": 61, "title": "President & COO", "yearBorn": 1962, "fiscalYear": 2022, "totalPay": 827718, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Beth P. Hecht J.D.", "age": 59, "title": "Chief Legal Officer & Corporate Secretary", "yearBorn": 1964, "fiscalYear": 2022, "totalPay": 638311, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Steven M. Pieper", "age": 46, "title": "Chief Financial Officer", "yearBorn": 1977, "fiscalYear": 2022, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Allison  Wey", "title": "Senior Vice President of Investor Relations & Corporate Communications", "fiscalYear": 2022, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Kenneth E. Johnson Pharm. D., Pharm.D.", "age": 60, "title": "Senior VP of Global Development & Medical Affairs", "yearBorn": 1963, "fiscalYear": 2022, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Kevin  McCulloch", "title": "Chief Commercial Officer", "fiscalYear": 2022, "exercisedValue": 0, "unexercisedValue": 0}], "auditRisk": 8, "boardRisk": 9, "compensationRisk": 10, "shareHolderRightsRisk": 8, "overallRisk": 10, "governanceEpochDate": 1709251200, "compensationAsOfEpochDate": 1672444800, "maxAge": 86400, "priceHint": 4, "previousClose": 2.19, "open": 2.18, "dayLow": 2.11, "dayHigh": 2.215, "regularMarketPreviousClose": 2.19, "regularMarketOpen": 2.18, "regularMarketDayLow": 2.11, "regularMarketDayHigh": 2.215, "beta": 1.213, "forwardPE": -8.875001, "volume": 1419304, "regularMarketVolume": 1419304, "averageVolume": 2380943, "averageVolume10days": 2013810, "averageDailyVolume10Day": 2013810, "bid": 2.11, "ask": 2.16, "bidSize": 300, "askSize": 400, "marketCap": 299164896, "fiftyTwoWeekLow": 1.25, "fiftyTwoWeekHigh": 3.26, "priceToSalesTrailing12Months": 1.8251333, "fiftyDayAverage": 2.6606, "twoHundredDayAverage": 2.2898, "currency": "USD", "enterpriseValue": 455905888, "profitMargins": -0.3798, "floatShares": 134206097, "sharesOutstanding": 140452992, "sharesShort": 9643267, "sharesShortPriorMonth": 9396337, "sharesShortPreviousMonthDate": 1706659200, "dateShortInterest": 1709164800, "sharesPercentSharesOut": 0.0687, "heldPercentInsiders": 0.03872, "heldPercentInstitutions": 0.4482, "shortRatio": 5.05, "shortPercentOfFloat": 0.0701, "bookValue": -0.049, "lastFiscalYearEnd": 1703980800, "nextFiscalYearEnd": 1735603200, "mostRecentQuarter": 1703980800, "netIncomeToCommon": -62255000, "trailingEps": -0.45, "forwardEps": -0.24, "enterpriseToRevenue": 2.781, "enterpriseToEbitda": -14.391, "exchange": "NMS", "quoteType": "EQUITY", "symbol": "XERS", "underlyingSymbol": "XERS", "shortName": "Xeris Biopharma Holdings, Inc.", "longName": "Xeris Biopharma Holdings, Inc.", "firstTradeDateEpochUtc": 1529587800, "timeZoneFullName": "America/New_York", "timeZoneShortName": "EDT", "uuid": "8f5f7125-cc84-3c21-a68b-9d3090e24887", "gmtOffSetMilliseconds": -14400000, "currentPrice": 2.13, "targetHighPrice": 6.0, "targetLowPrice": 4.0, "targetMeanPrice": 4.7, "targetMedianPrice": 4.5, "recommendationMean": 1.6, "recommendationKey": "buy", "numberOfAnalystOpinions": 5, "totalCash": 72451000, "totalCashPerShare": 0.516, "ebitda": -31680000, "totalDebt": 229191008, "quickRatio": 1.173, "currentRatio": 1.642, "totalRevenue": 163914000, "revenuePerShare": 1.191, "returnOnAssets": -0.08246, "returnOnEquity": -3.2420301, "freeCashflow": -19622876, "operatingCashflow": -47023000, "revenueGrowth": 0.339, "grossMargins": 0.82524, "ebitdaMargins": -0.19327, "operatingMargins": -0.22169, "financialCurrency": "USD", "trailingPegRatio": null, "__fetch_time": "2024-03-22"}]